A provision in the Dodd-Frank financial reform law that hiked monetary awards for taking evidence of wrongdoing directly to the Securities and Exchange Commission and the Commodities Futures Trading Commission is starting to reverberate. The Wall Street Journal reports that an existing whistleblower law resulted in a settlement of $750 million between GlaxoSmithKline and the Justice Department last week, with the former Glaxo quality assurance manager who was involved in line to receive $96 million. Companies fear new laws will lead to increased costs and undermine their internal fraud detection efforts.

Continue Reading for Free

Register and gain access to:

  • Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
  • Informative weekly newsletter featuring news, analysis, real-world cas studies, and other critical content
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.